Endpoints News

Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

Updated: Electra says $350M IPO will help it become a commercial biotech

FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease

Novartis’ TREM2 drug fails Phase 2 ALS trial

Ozempic-maker turns to Anthropic to turbocharge medical research

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

FDA names acting heads of drug and vaccine centers to permanent roles

Scientists Who Study Sleep and Narcolepsy Win Prestigious Lasker Award

New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show

Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility

Summit Packs A Punch For Merck's Keytruda

CBER official overruled review team’s rejection of new Replimune melanoma drug

Teva autoimmune antibody notches ph. 2 win in celiac disease

ARPA-H awards $125M for manufacturing custom RNA therapies on demand

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

GSK plans phase 3 after mRNA flu vaccine beats standard shots

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Lilly snags another Massachusetts biotech as local headcount surges past 1,400

Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

FDA approves new use of popular diabetes drug

Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months

An Experimental Single-Time Treatment Slashed Cholesterol for a Year

Genentech doubles down on ADC-resistance via $1B DualityBio pact

Alnylam’s heart drug troubles take center stage at a cardiology conference

FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients

Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal

Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg

U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute

Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

Opinion | Federal vaccine drama is causing great confusion. Your questions, answered.

A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High

Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T

AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review

Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal

US Employers Abandon Group Health Insurance as Price Hikes Bite

Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs

Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety

Regeneron backs $75M series A for antibody upstart Infinimmune

Silence Therapeutics aims at Takeda with new data in rare blood cancer

In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

FDA approves Replimune melanoma drug previously rejected twice

‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

AstraZeneca-Bristol Myers: Brace for a Biotech M&A Boom

Novo outlook hike falls flat as Wegovy pill sales fail to impress

AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up

Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues

9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson has proposed a $5.5 billion settlement to resolve ongoing legal challenges involving its talc-based baby powder products.

Argenx to Buy Forte Biosciences for $2.2 Billion

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Unpacking Anthropic's 100-day sprint into biopharma: Nobel hires, M&A and major ambition

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

The Great Peptide Cash Grab Has Begun

An FDA advisory panel review of seven peptides is sparking a debate over longevity medicine, public health risks, and potential multibillion-dollar markets.

Bristol Myers says it will build pharma's 'most powerful' AI supercomputer with Nvidia

Bristol Myers Squibb is partnering with Nvidia to build what it describes as the most powerful AI supercomputer in the life sciences industry.

The F.D.A. Approves a New Pill to Slash Cholesterol Levels

The FDA has approved Lipfendra, the first-of-its-kind oral PCSK9 inhibitor designed to significantly reduce cholesterol levels.

FDA releases 14 drug rejection letters after 3-month pause

FDA resumes releasing drug rejection letters after 3-month pause

The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy

An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising data from initial human trials.

'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive

6 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Compass says depression drug has long-lasting benefits

Compass Pathways reports positive six-month data for its psilocybin-based depression treatment, fueling market confidence and future filing plans.